Kisunla is currently undergoing a health technology assessment. Two newly approved Alzheimer’s treatments, Kisunla (donanemab ...

A new drug for treating early-stage Alzheimer’s disease has been administered for the first time in Taiwan on an 83-year-old ...

The new medications are currently not covered by Taiwan’s health insurance system but are available to patients who can pay ...

Kisunla is a newer treatment that works to slow down how fast Alzheimer’s progresses. It contains an antibody called donanemab-azbt, which targets and clears amyloid from the brain.

A U.K. health agency said the Alzheimer's drugs Kisunla and Leqembi are not cost-effective, meaning they won't be offered through the NHS.

INDIANAPOLIS, July 2, 2024 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) approved Kisunla™ (donanemab-azbt, 350 mg/20 mL once-monthly injection for IV infusion), Eli Lilly and ...

To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved ...

Kisunla is a prescription drug used to treat Alzheimer's disease. Find out whether it interacts with other drugs, alcohol, supplements, and more.

Kisunla (kih-SUHN-lah) is used to treat adults with early symptomatic Alzheimer's disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of disease.

TAIPEI (Taiwan News) — Far Eastern Memorial Hospital is set to become the first medical institution in Taiwan to administer ...

The authorization in Australia is for adult patients who are Apolipoprotein E-ε4 heterozygotes or non-carriers INDIANAPOLIS, May 21, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced ...

Kisunla (kih-SUHN-lah) is used to treat adults with early symptomatic Alzheimer's disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of disease.